(Total Views: 1166)
Posted On: 08/12/2020 12:51:54 AM
Post# of 148903
BREAKING NEWS. - CytoDyn reports exciting news from its top line Phase II trial data using Leronlimab!
Results place drug in lead position as a potential cure of all therapeutic treatments for COVID. Complete data now being forwarded to FDA for detailed analysis and potential consideration for Emergency Use Authorization to treat the deadly disease.
- Leronlimab repeatedly proven safe with little to no side effects in EIND use, HIV trials, Severe/Critical trial and now Phase II application.
- Patients receiving Leronlimab show 50% improvement in prevention of severe and other adverse effects vs.those taking placebo
- Drug meets Day 3 primary endpoint showing immediate health improvement for recipients in double blind study.
- Day 14 National Emergency Warning Scores (NEWS) twice as good in those receiving Leronlimab vs. those on placebo.
- Findings demonstrate Leronlimab reduces chance of patients advancing to hospitalization potentially saving thousands of lives and millions in healthcare costs to governments worldwide.
Top Line trial results are included below as well as senior leadership commentary on the significance of these breakthroughs and future milestones in this drugs development. CytoDyn will also hold a press briefing to answer investor’s questions tomorrow at 4PM EST. You may join the Q&A portion of the briefing by.......
THIS IS THE FORMAT I WOULD HAVE DONE THE PR IN. FORGIVE ME FOR THE ANY LACK OF ACCURACY IN THE DETAILS ABOVE.. JUST DEMOSTRATING LANGUAGE FOR THE TARGET AUDIENCE
Investor from another board ... maybe not a bad idea?
Results place drug in lead position as a potential cure of all therapeutic treatments for COVID. Complete data now being forwarded to FDA for detailed analysis and potential consideration for Emergency Use Authorization to treat the deadly disease.
- Leronlimab repeatedly proven safe with little to no side effects in EIND use, HIV trials, Severe/Critical trial and now Phase II application.
- Patients receiving Leronlimab show 50% improvement in prevention of severe and other adverse effects vs.those taking placebo
- Drug meets Day 3 primary endpoint showing immediate health improvement for recipients in double blind study.
- Day 14 National Emergency Warning Scores (NEWS) twice as good in those receiving Leronlimab vs. those on placebo.
- Findings demonstrate Leronlimab reduces chance of patients advancing to hospitalization potentially saving thousands of lives and millions in healthcare costs to governments worldwide.
Top Line trial results are included below as well as senior leadership commentary on the significance of these breakthroughs and future milestones in this drugs development. CytoDyn will also hold a press briefing to answer investor’s questions tomorrow at 4PM EST. You may join the Q&A portion of the briefing by.......
THIS IS THE FORMAT I WOULD HAVE DONE THE PR IN. FORGIVE ME FOR THE ANY LACK OF ACCURACY IN THE DETAILS ABOVE.. JUST DEMOSTRATING LANGUAGE FOR THE TARGET AUDIENCE
Investor from another board ... maybe not a bad idea?
(9)
(2)Scroll down for more posts ▼
